Clinical results, patient cases and future developments II: Head & neck cancer – Kevin Harrington on Vimeo
Randomised trial of pembrolizumab versus standard treatment in patients with recurrent or metastatic head and neck cancer - ecancer
T-VEC: what's next for oncolytic virotherapy and immuno-oncology? - Oncology Central
Improved survival, toxicity & QoL with pembrolizumab in head and neck cancer | VJOncology
ESMO Immuno-Oncology Congress 2022 What you can expect - YouTube
ICR researchers named among world's most influential scientists - The Institute of Cancer Research, London
Potential of immunotherapy in head and neck cancer | VJOncology
Longtime Fan Uses Ducks Hockey in His Cancer Fight
World-first centre for recurrent head & neck cancer - Professor Christopher Nutting Oncology
Kevin Harrington - Reader in Biological Cancer Therapies - Institute of Cancer Research | LinkedIn
Prof. Kevin Harrington | HSTalks
Loop | Kevin Joseph Harrington
SAB and I-O AB - T3 Pharma
Professor Kevin Harrington, I [IMAGE] | EurekAlert! Science News Releases
Professor Kevin Harrington | The Royal Marsden
Scientific Lecture | Kevin Harrington | FRONTAL
ESMO Immuno-Oncology Virtual Congress 2020 - YouTube
Professor Kevin Harrington - The Institute of Cancer Research, London
Game-changing drug doubles head and neck cancer survival | The Royal Marsden
Using Viruses to Treat Cancer | Prof Kevin Harrington | #SCIPEL 2015 | SCI - YouTube
Lapatinib not found to be beneficial in head and neck cancer with high risk of recurrence - ecancer
Kevin HARRINGTON | Institute of Cancer Research, London | Division of Radiotherapy and Imaging | Research profile
Potential of immunotherapy in head and neck cancer | VJOncology
Kevin Harrington | Speaker Agency, Speaking Fee, Videos | SPEAKING.com Keynote Speakers Bureau
